Vaccines, Blood & Biologics
Resources for You
HPV-010 Subject Treatment Allocation - Cervarix, September 26, 2007
To: Mr. Matthew Whitman
File: STN 125259/0 CERVARIX
RE: HPV-010 Subject Treatment Allocation
Date: September 26, 2007
Please refer to study HPV-010. Within the meta-analysis for potentially autoimmune events, subject PID #1658, who received either Gardasil or Cervarix, developed possible MS at 33 days after dose 2 of blinded study material. We acknowledge that the study is ongoing, but please provide the treatment allocation for this subject by the unblinded statistician as soon as possible.